Clinical trials: Influenza Vaccines
Human Influenza
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
Influenza vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml) of Hualan Biological Bacterin Co., Ltd (The subsidiary of Hualan Biological Engineering INC.) is applicable to the influenza immunity of age 3 and older…
- Trial name
- NCT01511744
- Testing
- Inactivated influenza split vaccine
- Where
- China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Influenza, Human
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
This Phase 3/4, randomized, observer-blind, multi-center study, stratified study evaluated the immune (antibody) response, efficacy and safety of a cell-derived quadrivalent subunit influenza virus vaccine (Seqirus QIVc) in…
- Trial name
- NCT03165617
- Testing
- QIVc, Non-influenza Comparator Vaccine
- Where
- 40 sites in Australia, Estonia and 6 more
- Volunteers
- 4,514 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318149
- Testing
- Fluarix, Fluarix-AS25, Fluarix-AS50
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one administration of OVX836 influenza vaccine at different dose levels (180µg, 300μg and 480μg) in order to assess the dose response of…
- Trial name
- NCT05060887
- Testing
- OVX836-003, Saline solution
- Where
- Belgium
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Osivax
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus…
- Trial name
- NCT00971906
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Influenza Challenge Study of VIS410 in Healthy Volunteers
A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).
- Trial name
- NCT02468115
- Testing
- VIS410
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Visterra, Inc.
Influenza A
Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)
This study has been designed to evaluate the safety and immunogenicity of two different formulations of FP-01.1 as well as build on the data set from the first in human study FP-01.1_CS_01.
- Trial name
- NCT01677676
- Testing
- FP-01.1, FP-01.1-Adjuvant
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Influenza
Phase 1 Study of ATR-002
This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.
- Trial name
- NCT04385420
- Testing
- ATR-002 MEK Inhibitor
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Atriva Therapeutics GmbH
Influenza A, Influenza Type B
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both…
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Trial name
- NCT05928507
- Testing
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Baebies, Inc.
Influenza
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 6 and 35 months.
- Trial name
- NCT00971321
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.
- Trial name
- FluMist (NCT03158038)
- Testing
- Monovalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Pandemic Influenza
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse…
- Trial name
- NCT00950456
- Testing
- H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 17 sites in Austria
- Volunteers
- 3,216 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Respiratory Viral Infection
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
- Trial name
- NCT07357051
- Testing
- JKN2301 Dry Suspension, Oseltamivir
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Influenza
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding…
- Trial name
- NCT01160237
- Testing
- PandemrixTM, FluarixTM/ Influsplit SSW® 2010/2011
- Where
- 5 sites in Germany
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00753272
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix TM
- Where
- 274 sites in United States, Belgium and 13 more
- Volunteers
- 43,695 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live…
- Trial name
- CAIVT (NCT00192322)
- Testing
- CAIV-T 10^7, CAIVT 10^5, TIV
- Where
- 2 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
To provide Centers for Biologic Evaluation and Research (CBER) with sera collected from healthy children receiving the 2007-2008 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study.
- Trial name
- NCT00561002
- Testing
- 2007-2008 Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children
This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.
- Trial name
- NCT00408395
- Testing
- Influenza vaccine
- Where
- Finland
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine
The primary objective is to assess the immunogenicity and safety and tolerability of two consecutive doses of H5 VLP Influenza vaccine given 21 days apart, at three dose levels: in part A: 20 µg, 30 µg and 45 µg combined with…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT01244867
- Testing
- 20 micrograms dose H5 VLP, 30 micrograms dose H5 VLP, 45 micrograms dose H5 VLP
- Where
- Canada
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Medicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.